207 related articles for article (PubMed ID: 18482778)
21. Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages.
Aquaro S; Svicher V; Ceccherini-Silberstein F; Cenci A; Marcuccilli F; Giannella S; Marcon L; Caliò R; Balzarini J; Perno CF
J Antimicrob Chemother; 2005 Jun; 55(6):872-8. PubMed ID: 15845785
[TBL] [Abstract][Full Text] [Related]
22. The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.
Auwerx J; Stevens M; Van Rompay AR; Bird LE; Ren J; De Clercq E; Oberg B; Stammers DK; Karlsson A; Balzarini J
J Virol; 2004 Jul; 78(14):7427-37. PubMed ID: 15220416
[TBL] [Abstract][Full Text] [Related]
23. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
Mathiesen S; Dam E; Roge B; Joergensen LB; Laursen AL; Gerstoft J; Clavel F
Antivir Ther; 2007; 12(3):335-43. PubMed ID: 17591023
[TBL] [Abstract][Full Text] [Related]
24. Diminished HIV-1 sensitivity to stavudine in patients on prolonged therapy occurs only at low levels and cannot be attributed to any single amino acid substitution in reverse transcriptase.
Salomon H; Montaner JS; Belmonte A; Wainberg MA
Antivir Ther; 1998; 3(3):177-82. PubMed ID: 10682135
[TBL] [Abstract][Full Text] [Related]
25. Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-beta-D-1',3'-dioxolan guanine.
Feng JY; Myrick F; Selmi B; Deval J; Canard B; Borroto-Esoda K
Antiviral Res; 2005 Jun; 66(2-3):153-8. PubMed ID: 15885814
[TBL] [Abstract][Full Text] [Related]
26. Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5).
Hachiya A; Aizawa-Matsuoka S; Tanaka M; Takahashi Y; Ida S; Gatanaga H; Hirabayashi Y; Kojima A; Tatsumi M; Oka S
Antimicrob Agents Chemother; 2001 Feb; 45(2):495-501. PubMed ID: 11158746
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of mixtures of wild-type HIV-1 and HIV-1 with resistance point mutations against reverse transcriptase inhibitors.
Villahermosa ML; Contreras G; Pérez-Alvarez L; Bru F; Medrano L; Delgado E; Colomo C; Thomson M; Nájera R
Antivir Ther; 1998; 3(4):221-7. PubMed ID: 10682142
[TBL] [Abstract][Full Text] [Related]
28. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
[TBL] [Abstract][Full Text] [Related]
29. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.
Ntemgwa M; Wainberg MA; Oliveira M; Moisi D; Lalonde R; Micheli V; Brenner BG
Antimicrob Agents Chemother; 2007 Nov; 51(11):3861-9. PubMed ID: 17724152
[TBL] [Abstract][Full Text] [Related]
30. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
[TBL] [Abstract][Full Text] [Related]
31. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons.
Garcia-Lerma JG; Nidtha S; Blumoff K; Weinstock H; Heneine W
Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13907-12. PubMed ID: 11698656
[TBL] [Abstract][Full Text] [Related]
32. Transmission of human immunodeficiency virus type 1 nevirapine resistance mutation K103N from a treatment-naive mother to her child.
Schmitz T; Kleinkauf N; Klempa B; Ringe H; Varnholt V; Grosch-Wörner I
Pediatr Infect Dis J; 2006 Mar; 25(3):275-6. PubMed ID: 16511398
[TBL] [Abstract][Full Text] [Related]
33. Stavudine in the face of cross-resistance between HIV-1 nucleoside reverse transcriptase inhibitors: a review.
Lafeuillade A; Tardy JC
AIDS Rev; 2003; 5(2):80-6. PubMed ID: 12876897
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel.
Turner D; Shahar E; Katchman E; Kedem E; Matus N; Katzir M; Hassoun G; Pollack S; Kessner R; Wainberg MA; Avidor B
J Med Virol; 2009 Sep; 81(9):1509-12. PubMed ID: 19626612
[TBL] [Abstract][Full Text] [Related]
35. Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region.
Villena C; Prado JG; Puertas MC; Martínez MA; Clotet B; Ruiz L; Parkin NT; Menéndez-Arias L; Martinez-Picado J
J Virol; 2007 May; 81(9):4713-21. PubMed ID: 17314158
[TBL] [Abstract][Full Text] [Related]
36. Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro.
Nitanda T; Wang X; Kumamoto H; Haraguchi K; Tanaka H; Cheng YC; Baba M
Antimicrob Agents Chemother; 2005 Aug; 49(8):3355-60. PubMed ID: 16048947
[TBL] [Abstract][Full Text] [Related]
37. Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages.
Perez-Bercoff D; Wurtzer S; Compain S; Benech H; Clavel F
J Virol; 2007 May; 81(9):4540-50. PubMed ID: 17287264
[TBL] [Abstract][Full Text] [Related]
38. Assessment of the susceptibility of mutant HIV-1 to antiviral agents.
Wang YJ; McKenna PM; Hrin R; Felock P; Lu M; Jones KG; Coburn CA; Grobler JA; Hazuda DJ; Miller MD; Lai MT
J Virol Methods; 2010 May; 165(2):230-7. PubMed ID: 20153375
[TBL] [Abstract][Full Text] [Related]
39. Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania.
Paraschiv S; Otelea D; Baicus C; Tinischi M; Costache M; Neaga E
Int J Infect Dis; 2009 Jan; 13(1):81-9. PubMed ID: 18632295
[TBL] [Abstract][Full Text] [Related]
40. Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors.
Masquelier B; Race E; Tamalet C; Descamps D; Izopet J; Buffet-Janvresse C; Ruffault A; Mohammed AS; Cottalorda J; Schmuck A; Calvez V; Dam E; Fleury H; Brun-Vézinet F;
Antimicrob Agents Chemother; 2001 Jun; 45(6):1836-42. PubMed ID: 11353634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
